What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?

BACKGROUND/AIM: An effective postprogression treatment of lenvatinib (LEN) against unresectable hepatocellular carcinoma (u-HCC) has not been established. We aimed to elucidate the clinical role of continuing LEN beyond progression of disease (PD). METHODS: From March 2018 to October 2020, 99 u-HCC...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Liver Cancer
Autors principals: Hiraoka, Atsushi, Kumada, Takashi, Tada, Toshifumi, Kariyama, Kazuya, Tani, Joji, Fukunishi, Shinya, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Kawata, Kazuhito, Yasuda, Satoshi, Toyoda, Hidenori, Ohama, Hideko, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Michitaka, Kojiro, Hiasa, Yoichi, Kudo, Masatoshi
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2021
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8077500/
https://ncbi.nlm.nih.gov/pubmed/33977088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513355
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars